Letters to the Editor
Hormone Replacement Therapy and the General Practitioner From Mr E Schleyer-Saunders Wimpole Street, London WI Sir, With regard to the meeting on hormone replacement therapy (HRT) and the general practitioner (June Proceedings, p 423), I would like to express some opinions based on a thirty-seven-year study of the climacteric (Schleyer-Saunders 1960 , 1966 , 1971 , 1976a . The report is a valuable contribution to the better understanding of the role that the general practitioner can play in the management of the menopause. Though HRT has been practised in other countries for many years, it is only the last ten years that have brought a distinct change in attitude in the medical profession in this country. This is well demonstrated by the numerous conferences and symposia now being held here, concerned with the advantages and long-term effects of treating menopausal symptoms and preventing some of the degenerative disorders of later life.
It is now generally accepted that lack of oestrogen with progressive age is mainly responsible for the devlopment of the menopausal syndrome and that replacement therapy with cestrogens is the correct treatment. The symptoms of cestrogen lack are well known and include hot flushes, sweating, excessive fatigue, insomnia, irritability, impairment of memory, lack of libido, mood changes with depression and joint pains. Local changes in the vagina lead to severe vaginitis and dyspareunia; interference with bone resorption may lead to osteoporosis and changes in the urinary tract are responsible for a variety of urinary disorders.
I would question the statement that only 20 0 of women found menopausal symptoms so incapacitating that they sought medical help. A figure of 200% might be correct if hot flushes and night sweats were the only serious symptoms. However, if other symptoms are included, such as mood change and depression, irritability and lack of confidence, then a figure of 40 % is more realistic.
Of those women who do consult their general practitioner in the UK, less than 1 % are given oestrogens. Reassurance by the general practitioner is helpful, but treatment with tranquillizers is of little value. Antidepressants are of some value but oestrogen therapy should be the first line of treatment. Oral cestrogens alone, or in conjunction with a progestogen, given cyclically, is the most common method of administration.
Treatment by implantation of pellets ofcestradiol with progesterone and sometimes testosterone has certain advantages over oral treatment. There are no untoward gastric, intestinal or liver side-effects; the effective dose of a combination of testosterone is less than the dose of either hormone given separately and the hormones are synergistic in their anabolic properties. Psychologically the patient is not continually reminded of her condition and this method is particulary useful in patients who forget to take tablets. Irregular bleeding can be prevented by producing a withdrawal bleed with a small fiveday course of progestogen. CEstradiol implantation is certainly the best method of treatment for the hysterectomized patient.
To my knowledge, no case of thromboembolic disease has been found among 2000 cases treated by this method in my practice. A recent article by Hunter et al. (1977) confirmed that with cestradiol implants there was no change in coagulation factors 5, 7, 9 and 10. The technique is simple, takes a few minutes and is performed under local anesthetic. Naturally if irregular bleeding occurs despite adding a progestogen, then curettage is necessary. This can be done simply with the Vabra aspirator without an anxsthetic.
Perhaps the single most important factor in limiting the widespread use of replacement therapy is the possible association between estrogens and cancer of the endometrium and breast. I do not believe that breast cancer is stimulated by cestrogens, though it must be said that a small proportion of breast cancers are cestrogensensitive. This experience has been borne out by a large series in the US (CA -Cancer Journal for Clinicians 1968) where no increased incidence in breast cancer in patients being treated with cestrogen therapy was noted, and some workers even believe that cestrogens may be protective in some way (Byrd & Burch 1973 , Magarey & Baum 1971 . The paper by Ziel & Finkle (1975) falsely spread alarm amongst the profession; their series was small, poorly controlled and there was no evidence of an independent pathologist examining the specimens.
Any treatment method must have some disadvantages, but these must be weighed against the calcuable help that can be given to so many woman suffering from the symptoms of the climacteric. It is heartening to see that a number of centres in the UK, notably in London (St Sir, Your report (June Proceedings, p 423) 'Hormone Replacement Therapy and the General Practitioner' raises some interesting issues. I agree completely with Mrs Jean Robinson that there is a need for doctors to listen and to take much more notice of menopausal symptoms, but we should be careful to avoid assuming that all emotional and psychological disturbances at the time of the menopause can be relieved by an attractive packet of pills. Our society is only too ready to take the short cut. It is easier to write a prescription than to listen to problems, which are the product of our social organization and, in particular, of the role that middle-aged women are forced to play. I am glad that 'liberated women' are not likely to accept decades of steroid therapy as your report suggests they may. Such women are much more likely to reject glib medical reassurance that a pill a day will resolve all their problems. Neither are they likely to accept without question the motives of the pharmaceutical industry supporting menopausal clinics.
I welcome technological advance to make people less and not more dependent on doctors, and to enable us to spend more time listening to each other. Yours Sir, There is abundant reason to search for further ttiological mechanisms for ischxmic heart disease, for risk factors known at present do not fully account for its occurrence. One suggestion has been that coronary disease is frequently the consequence of 'premyxcedema'. This was defined by Dr Fowler et al. (1970, Lancet ii, 488) as a state of early thyroid failure in which normal plasma thyroid hormone levels are maintained by an increased secretion of TSH and in which hypercholesterolhmia is a characteristic feature. Circulating thyroid antibodies were said to be a common finding. Thus hypercholesterolhmia was due to thyroid disease, but occurred in the absence of clinical evidence of hypothyroidism and in the presence of normal plasma levels of thyroid hormone. This entity has been held by Dr Fowler to be a common cause of ischemic heart disease in the community, presumably mediated by hypercholesterolmmia (May Proceedings, p 297).
In several years of running a lipid clinic I have seen some 1500 hyperlipidaemic patients, many of them with ischemic heart disease. Underlying causes were often present, amongst which overt hypothyroidism was prominent. For five years, our routine investigations for secondary hyperlipidewmia included TSH assay. On no occasion did this lead to a clinically-unsuspected diagnosis of hypothyroidism. This experience is quite at variance with that of Baschieri et al., quoted in Dr Fowler's editorial.
Is the triad of ischemic heart disease, hyperlipidcmia and the presence of thyroid antibodies a recognizable entity? Heinonen et al. (1972, Lancet i, 785) have failed to confirm an association between ischtmic heart disease and thyroid antibodies. Tunbridge (1976, MD Thesis, University of Cambridge) observed no significant association in a community study, between thyroid antibodies or high TSH levels and serum lipid concentration or lipoprotein patterns. However, a high TSH was associated in women, but not in men, with minor ECG abnormalities and with symptoms suggestive of cardiac ischemia.
A further reason for questioning the importance of the concept of premyxcedema, is the absence of any plausible mechanism by which early thyroid disease could result in hypercholesterolemia.
Plasma levels of thyroid hormone are by definition normal; I do not see how the hepatic mechanisms for excretion and degradation of cholesterol could anticipate future thyroid insufficiency. This leaves the possibility that high TSH levels might lead to chronic hypercholesterolemia in man. While TSH
